Pan-cancer analysis reveals that G6PD is a prognostic biomarker and therapeutic target for a variety of cancers.
G6PD
drug resistance
pan-cancer
survival analysis
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
19
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Despite accumulating evidence revealing that Glucose-6-phosphate dehydrogenase (G6PD) is highly expressed in many tumor tissues and plays a remarkable role in cancer tumorigenesis and progression, there is still a lack of G6PD pan-cancer analysis. This study was designed to analyze the expression status and prognostic significance of G6PD in pan-cancer. G6PD expression data were obtained from multiple data resources including the Genotype-Tissue Expression, the Cancer Genome Atlas, and the Tumor Immunity Estimation Resource. These data were used to assess the G6PD expression, prognostic value, and clinical characteristics. The ESTIMATE algorithms were used to analyze the association between G6PD expression and immune-infiltrating cells and the tumor microenvironment. The functional enrichment analysis was also performed across pan-cancer. In addition, the GDSC1 database containing 403 drugs was utilized to explore the relationship between drug sensitivity and G6PD expression levels. Furthermore, we also performed clinical validation and G6PD expression was upregulated in most cancers compared to their normal counterparts. The study also revealed that G6PD expression was a prognostic indicator and high levels of G6PD expression were correlated with worse clinical prognosis including overall survival, disease-specific survival, and progression-free interval in multiple cancers. Furthermore, the G6PD level was also related to cancer immunity infiltration in most of the cancers, especially in KIRC, LGG, and LIHC. In addition to this, G6PD expression was positively related to pathological stages of KIRP, BRCA, KIRC, and LIHC. Functional analysis and protein-protein interactions network results revealed that G6PD was involved in metabolism-related activities, immune responses, proliferation, and apoptosis. Drug sensitivity analysis showed that IC50 values of most identified anti-cancer drugs were positively correlated with the G6PD expression. Notably, G6PD may serve as a potential prognostic biomarker for cancers and may be a potential therapeutic target gene for tumor therapy.
Sections du résumé
Background
UNASSIGNED
Despite accumulating evidence revealing that Glucose-6-phosphate dehydrogenase (G6PD) is highly expressed in many tumor tissues and plays a remarkable role in cancer tumorigenesis and progression, there is still a lack of G6PD pan-cancer analysis. This study was designed to analyze the expression status and prognostic significance of G6PD in pan-cancer.
Methods
UNASSIGNED
G6PD expression data were obtained from multiple data resources including the Genotype-Tissue Expression, the Cancer Genome Atlas, and the Tumor Immunity Estimation Resource. These data were used to assess the G6PD expression, prognostic value, and clinical characteristics. The ESTIMATE algorithms were used to analyze the association between G6PD expression and immune-infiltrating cells and the tumor microenvironment. The functional enrichment analysis was also performed across pan-cancer. In addition, the GDSC1 database containing 403 drugs was utilized to explore the relationship between drug sensitivity and G6PD expression levels. Furthermore, we also performed clinical validation and
Results
UNASSIGNED
G6PD expression was upregulated in most cancers compared to their normal counterparts. The study also revealed that G6PD expression was a prognostic indicator and high levels of G6PD expression were correlated with worse clinical prognosis including overall survival, disease-specific survival, and progression-free interval in multiple cancers. Furthermore, the G6PD level was also related to cancer immunity infiltration in most of the cancers, especially in KIRC, LGG, and LIHC. In addition to this, G6PD expression was positively related to pathological stages of KIRP, BRCA, KIRC, and LIHC. Functional analysis and protein-protein interactions network results revealed that G6PD was involved in metabolism-related activities, immune responses, proliferation, and apoptosis. Drug sensitivity analysis showed that IC50 values of most identified anti-cancer drugs were positively correlated with the G6PD expression. Notably,
Conclusion
UNASSIGNED
G6PD may serve as a potential prognostic biomarker for cancers and may be a potential therapeutic target gene for tumor therapy.
Identifiants
pubmed: 37601657
doi: 10.3389/fonc.2023.1183474
pmc: PMC10435888
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1183474Informations de copyright
Copyright © 2023 Zeng, Li, Shu, Pang, Wang, Cai, Liao, Xiao, Chong, Gong and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Front Oncol. 2019 Nov 01;9:1143
pubmed: 31737570
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Bioorg Med Chem Lett. 2021 May 15;40:127905
pubmed: 33689874
Int J Oncol. 2018 Sep;53(3):1055-1068
pubmed: 30015875
Nat Cell Biol. 2011 Mar;13(3):310-6
pubmed: 21336310
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
Free Radic Biol Med. 2012 Aug 1;53(3):421-36
pubmed: 22580150
BMC Bioinformatics. 2016 Feb 06;17:72
pubmed: 26852330
Mol Cancer. 2021 Feb 5;20(1):28
pubmed: 33546704
Chemotherapy. 2021;66(5-6):179-191
pubmed: 34775382
Acta Biochim Biophys Sin (Shanghai). 2018 Apr 1;50(4):370-380
pubmed: 29471502
Front Pharmacol. 2022 Oct 19;13:1007279
pubmed: 36339598
Int J Mol Sci. 2020 Jan 31;21(3):
pubmed: 32023830
Trends Biochem Sci. 2014 Aug;39(8):347-54
pubmed: 25037503
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
BMC Cancer. 2013 May 22;13:251
pubmed: 23693134
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Biochim Biophys Acta. 2016 Sep;1863(9):2245-54
pubmed: 27217331
Cancer Biother Radiopharm. 2009 Feb;24(1):81-90
pubmed: 19243250
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
IUBMB Life. 2012 May;64(5):362-9
pubmed: 22431005
Mol Cell. 2020 Jun 18;78(6):1019-1033
pubmed: 32559423
Genes Dis. 2017 Sep 23;4(4):196-203
pubmed: 30258923
Nat Chem Biol. 2020 Jul;16(7):731-739
pubmed: 32393898
J Mol Histol. 2022 Apr;53(2):215-225
pubmed: 35028787
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Signal Transduct Target Ther. 2021 Feb 4;6(1):46
pubmed: 33536406
Cell Rep. 2020 Jul 7;32(1):107848
pubmed: 32640218
Oncotarget. 2017 Nov 20;8(65):109043-109060
pubmed: 29312589
J Exp Clin Cancer Res. 2017 Nov 23;36(1):166
pubmed: 29169374
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
J Cell Mol Med. 2019 May;23(5):3451-3463
pubmed: 30809937
Int J Oncol. 2020 Jul;57(1):197-212
pubmed: 32319593
Oncogene. 2017 Nov 9;36(45):6282-6292
pubmed: 28692052
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93
pubmed: 20421486
Free Radic Res. 2016 Oct;50(10):1047-1064
pubmed: 27684214
Cell. 2018 Apr 5;173(2):530
pubmed: 29625059
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Oncol Rep. 2020 Dec;44(6):2325-2336
pubmed: 33125150
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Cell Death Dis. 2019 Jul 8;10(7):525
pubmed: 31285420
Int J Oncol. 2018 Oct;53(4):1703-1712
pubmed: 30066842
Biochem Biophys Res Commun. 2018 Mar 25;498(1):207-213
pubmed: 29501744
Cell Syst. 2018 Mar 28;6(3):282-300.e2
pubmed: 29596783
Cell Cycle. 2013 Dec 15;12(24):3720-6
pubmed: 24270845
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941691
Nat Commun. 2013;4:2612
pubmed: 24113773
Asian Pac J Cancer Prev. 2018 Apr 27;19(4):1069-1073
pubmed: 29699064
Cancer Lett. 2020 Nov 1;492:1-10
pubmed: 32712233
Bioinformatics. 2017 Oct 01;33(19):3036-3042
pubmed: 28575181